Navigation Links
Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839

LOUISVILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/ -- Replidyne, Inc. today announced results from three Phase I trials studying REP8839, a novel topical antibiotic that has shown potent in vitro activity against major skin pathogens including methicillin-resistant S. aureus (MRSA). The results of the Phase I trials show that topically applied REP8839 appears safe, well-tolerated and associated with low systemic exposure, or drug absorption into the bloodstream, which is desirable for a topical antibiotic treatment. Based on these results, Replidyne plans to initiate Phase II trials in children with impetigo, the most common bacterial skin infection, by the end of the year.

"REP8839 is a promising development candidate and has the potential to be an important treatment option for physicians in the ongoing fight against drug-resistant infections including MRSA, a growing public health concern," said Kenneth J. Collins, Replidyne's President and Chief Executive Officer. "With these safety data, we intend to move forward into Phase II trials to study the safety and efficacy of REP8839 in patients with impetigo and other skin and wound infections."

REP8839 was tested in three Phase I trials which collectively enrolled over 400 subjects. In the first Phase I trial, safety, tolerability and skin irritancy were tested following repeated daily application of REP8839, at three drug concentrations (1%, 2% and 4%), on intact and abraded skin. Irritancy scores comparable to placebo were recorded for all REP8839 exposed test subjects. In the second study, in addition to safety, tolerability and dermal irritancy, systemic exposure was examined following repeated daily application of REP8839 on a larger surface area of intact and abraded skin. In all subjects, REP8839 was associated with low systemic exposure and low skin irritancy. In the third study, a 2% formulation of REP8839 was tested for its ability
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Replidyne Phase II Pediatric Trial Meets Primary Objective
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/24/2014)... CHAPEL HILL, N.C. , Dec. 23, 2014 /PRNewswire/ ... marketplace success. As the key link between the medical ... will grow even more in the coming years as ... relationships. According to research by benchmarking ... and MSLs can gain an important edge is by ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... "US Self-monitoring Blood Glucose Market" report to ... This market insight focuses on the developments ... the United States . Reimbursement analysis and the ... analyses for more than 73 SMBG meters have been ...
(Date:12/22/2014)... 2014 Cyberonics, Inc. (NASDAQ: CYBX ), ... management of epilepsy, today announced it will participate in the ... January 14, 2015, in San Francisco . ... Executive Officer, will speak at 11:00 AM Pacific Time.  A ... clicking on the Investor Relations link on the Cyberonics home ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... (Nasdaq: NVAX ) a clinical-stage vaccine company, ... of Novavax will be presenting at the Stifel Nicolaus ... 17, 2010 at 10:20am local time at the Four ... company overview, outline its competitive position and characterize Novavax,s ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ... million shares of its common stock pursuant to an effective ... Inc. is the sole book-running manager of the offering and ... to purchase up to 1,245,000 additional shares. Halozyme intends to ...
Cached Medicine Technology:Halozyme Therapeutics Announces Public Offering of Common Stock 2Halozyme Therapeutics Announces Public Offering of Common Stock 3
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping tips ... the models at LunaDress.co.uk come with big discounts, up to 80 ... can turn out to be a most exciting memory and can ... bring surprise to a wedding. On the updated fashion blog, ladies ... for a big day . , Going out with friends to ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
(Date:12/24/2014)... Epigenetics finds applications in a large number ... discovery, developmental biology, and research for metabolic and genetic ... most widely used techniques for the discovery and development ... cancer is rapidly growing worldwide. In 2012, there were ... and 32.6 million people living with cancer (within five ...
(Date:12/24/2014)... Dr. Vu Ho, a Dallas based facial plastic ... med-spa with the addition of new Silk Peel skin ... and services. , “Silk Peel is a procedure that ... “As a result it can address issues like acne ... or blemishes.” , Similar to microdermabrasion, Silk Peel ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... Inc. (NYSE: MYL ),today announced that its subsidiary, ... and Drug Administration (FDA) for its,Abbreviated New Drug Application ... Zaleplon Capsules are the generic version of King Pharmaceuticals,Sonata(R) ... for,the 12 months ending March 31, 2008, according to ...
... news that DuPont,s Teflon chemicals likely,contaminate area residential wells. ... level., - Private residential well contamination with PFOA ... private drinking water wells and warnings,issued to residents in ... DEEPWATER, N.J., June 9 A coalition of,environmental ...
... ALEXANDRIA, Va., June 9 The National,Community ... of,Compounding Pharmacists (IACP) are collaborating to increase ... engage in compounding.,IACP has established a satellite ... their Director of Public Affairs, Sarah R. ...
... and Good Health this Father,s Day, Nearly 40 Million ... ... 9 Families sick and tired of Dad,s raucous,snoring, incessant allergic ... Snoring Center: a unique medical practice dedicated,exclusively to the evaluation and ...
... A new study demonstrates that microRNAs can modulate the ... may play a significant role in some human cancers. ... issue of the journal Cancer Cell, is likely to ... and leukemias. , MicroRNAs (miRNAs) are small noncoding pieces ...
... way solid tumors adapt the body,s machinery to bring ... these tumors stronger. , "In a sense, these therapies ... D.V.M., Ph.D., professor of radiation oncology at Duke University ... killing many if not most tumor cells, you are ...
Cached Medicine News:Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 2Health News:New Jersey Coalition Calls for Investigation of Private Wells to Protect Families from PFOA in Drinking Water 3Health News:Pharmacist Associations Partner to Increase the Voice of Pharmacy 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 2Health News:Stop Dad's Sleepless Nights - and the Sniffles - With the Snoring Center 3Health News:MicroRNA controls expression of oncogenes 2Health News:Solid tumor cells not killed by radiation and chemotherapy become stronger 2
...
Angled 45 Degrees to Right, 9.5mm blade, gently curved .5x .25mm blunt tips; Lower blade is 0.5mm longer; 14mm from mid screw to tip; (Available in left and right;) overall length 120mm; Stainless ...
16mm Slightly Curved sharp Tips; overall length 120mm; Stainless Steel...
16mm from Mid-Screw to Blunt Tips, Gently Curved Blades; overall length 120mm; Stainless Steel...
Medicine Products: